Literature DB >> 6104978

Some further evidence for partial agonist activity of labetalol.

A J Riley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6104978      PMCID： PMC1429955          DOI： 10.1111/j.1365-2125.1980.tb05849.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  3 in total

1.  [Alpha- and beta-adrenoceptor blocking actions of labetalol and effects on the myocardial function, coronary circulation and myocardial energy metabolism thereof (author's transl)].

Authors:  Y Katano; K Takeda; Y Nakagawa; T Hashimoto; M Nakazawa; T Tsukada; T Otorii; S Imai
Journal:  Nihon Yakurigaku Zasshi       Date:  1978-10

Review 2.  A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.

Authors:  R T Brittain; G P Levy
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

3.  Beta-adrenoceptor agonist activity of labetolol on the isolated uterus of the rat.

Authors:  B Carey; E T Whalley
Journal:  Br J Pharmacol       Date:  1979-09       Impact factor: 8.739
  3 in total
  6 in total

Review 1.  The choice of antihypertensive therapy in the diabetic patient.

Authors:  A D Struthers
Journal:  Postgrad Med J       Date:  1985-07       Impact factor: 2.401

2.  The dose dependency of the alpha-adrenoceptor antagonist and beta-adrenoceptor partial agonist activity of dilevalol and labetalol in man.

Authors:  T C Tham; J P McKaigue; S Guy; R G Shanks; J G Riddell
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

3.  Transfer of labetalol into amniotic fluid and breast milk in lactating women.

Authors:  N O Lunell; J Kulas; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 4.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

5.  Circulatory and metabolic effects of a combined alpha- and beta-adrenoceptor blocker (labetalol) in hypertension of pregnancy.

Authors:  N O Lunell; P Hjemdahl; B B Fredholm; H Nisell; B Persson; J Wager
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

6.  Carvedilol inhibits EGF-mediated JB6 P+ colony formation through a mechanism independent of adrenoceptors.

Authors:  Kristan H Cleveland; Sherry Liang; Andy Chang; Kevin M Huang; Si Chen; Lei Guo; Ying Huang; Bradley T Andresen
Journal:  PLoS One       Date:  2019-05-20       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.